http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2409406-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_feef2d2e76e40b47e9cf04aa559bd5ba |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
| filingDate | 2010-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5db0ac1c7c485235a645c8529efbdfa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36bcbd368e3bbffce40b6d3a141ddaa8 |
| publicationDate | 2013-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2409406-T3 |
| titleOfInvention | Use of rosuvastatin lactoles as medicines |
| abstract | A compound of Formula I and pharmaceutically acceptable salts and solvates thereof: for use in the treatment of a condition that can be treated by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), where the condition that can be treated by inhibiting HMG-CoA reductase is selected from the group consisting of: hypercholesterolemia, atherosclerosis, hyperlipidemia, cardiovascular disease, coronary heart disease, myocardial infarction, stroke, peripheral artery disease, inflammation, dementia, cancer, nuclear cataracts, diabetes and hypertension, where in addition: R1 and R4 are independently selected from the group consisting of: hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, aryl, C1-4-aryl alkyl , heterocyclyl and C1-4 alkyl-heteroaryl; R2 is -S (O) 2R9 where R9 is C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkyl-aryl or aryl; R3 is hydrogen, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl or aryl; R5 and R6 are independently selected from the group consisting of: hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 3-6 cycloalkyl, aryl, C 1-6 alkyl aryl, C 1-6 alkaryl, heteroaryl, C1-6 alkanoyl-heteroaryl and C1-6 alkyl-heteroaryl; with the proviso that R5 and R6 are never the two hydrogen; R7 and R8 are independently selected from the group consisting of: H, C1-4 alkyl and halo; X is - (CRaRb) m (CRa> = CRb) n (CRaRb) or where Ra and Rb are independently selected from the group consisting of: H, methyl, ethyl and halo and m, nyo are independently 0, 1, 2 or 3 with the proviso that m + n + or not more than 3; and where each of the above R1 to R9 groups may be, when chemically possible, optional and independently substituted with 1 to 5 groups independently selected in each case from the groups consisting of: halo, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, hydroxy and cyano. |
| priorityDate | 2009-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 120.